Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor.
about
HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin familyNovel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophagesInfluenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin IIISerpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replicationAnti-HSV activity of serpin antithrombin III.In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes.The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors.CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibitionControl of HIV-1 infection by soluble factors of the immune response.Uniquely altered transcripts are associated with immune preservation in HIV infection.Protein kinase C and NF-κB-dependent CD4 downregulation in macrophages induced by T cell-derived soluble factors: consequences for HIV-1 infectionEffects of anticoagulant strategies on activation of inflammation and coagulation.Noncytotoxic suppression of human immunodeficiency virus type 1 transcription by exosomes secreted from CD8+ T cells.Induction of a Soluble Anti-HIV-1 factor (s) with IFN-γ, IL-10, and β-Chemokine Modulating Activity by an Influenza-Bacterial Polyantigenic Mixture.Pharmacology and clinical applications of human recombinant antithrombin.The heparin-binding site of antithrombin is crucial for antiangiogenic activityInhibition of HCV by the serpin antithrombin III
P2860
Q28214202-E4A1A6BB-1277-4067-89FE-3E2CD1585C95Q30445480-C47C0BF2-C555-4E32-89C8-02443577D30FQ33679314-72BE3B4E-87AF-460A-BB86-1F0825B54CA5Q33886860-54251CD3-3820-422A-8801-3E81B99D9265Q34152714-61334C21-7E90-4473-987B-96B7FBFA1DFDQ34469655-053DFE97-C438-43DB-AAA1-5296615EEF03Q34870367-04690751-DA39-43A8-8D18-F3BBA13E49A2Q35020718-5ECAFB98-A094-4BD2-887A-22464741EA83Q35752416-9047D972-5335-4852-82B4-7F91DDDC2335Q36325586-41492DF7-2F97-4CA3-A908-F4893421D0E0Q36655072-5B91CADC-E4E3-4ACB-B537-0A222691BA98Q36842724-4B1E27EF-5AA2-429E-8B56-CC723E5CEE97Q37157103-C50E80C5-BF6E-45BC-91CF-3D0989B6B231Q37375957-787A0F9A-4E37-4FF3-A79D-020C6D3AA4DBQ37763191-E588D8D7-382D-47A8-B5E6-567EBFB22A2EQ41845994-1D4C2AAE-90AB-4ACA-B31E-5BCB5D441A97Q42406960-94961422-5C7F-411A-BC57-723A2331D08B
P2860
Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Purification of a modified for ...... CD8+ T-cell antiviral factor.
@en
Purification of a modified for ...... CD8+ T-cell antiviral factor.
@nl
type
label
Purification of a modified for ...... CD8+ T-cell antiviral factor.
@en
Purification of a modified for ...... CD8+ T-cell antiviral factor.
@nl
prefLabel
Purification of a modified for ...... CD8+ T-cell antiviral factor.
@en
Purification of a modified for ...... CD8+ T-cell antiviral factor.
@nl
P2093
P2860
P356
P1476
Purification of a modified for ...... CD8+ T-cell antiviral factor.
@en
P2093
Andrew D Luster
Nancy Brown
Ralf Geiben-Lynn
P2860
P304
42352-42357
P356
10.1074/JBC.M207079200
P407
P577
2002-08-20T00:00:00Z